TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06137612

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: axial 2D rAMIRA (radially sampled averaged magnetization inversion recovery acquisitions) imaging at selected levels of cervical and thoracic spinal cord at the intervertebral disc levels perpendicular to the spinal cord.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: axial 2D rAMIRA (radially sampled averaged magnetization inversion recovery acquisitions) imaging at selected levels of cervical and thoracic spinal cord at the intervertebral disc levels perpendicular to the spinal cord.
Study: NCT04669743

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone exposure
Description: Exposures will take place at the UCSF Human Exposure Chamber Core Facility. Ozone will be added to the air in the chamber and concentration measured every 30 seconds. Subjects will exercise for two 15-minute intervals of each hour on a cycle ergometer, and will rest for two 15-minute intervals between exercise sessions. The rate of exercise will be individually adjusted to produce a targeted minute ventilation of 15-20 L/min/m2 body surface area. Subjects will be sent home post-exposure and will return to the laboratory on the following day and six days after the exposure for bronchoscopy.
Study: NCT03225898

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Exercise with Blood Flow Restriction
Description: A cuff will be used to restrict blood flow to the extremities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: High-intensity Resistance Exercise
Description: Participants will follow a conventional resistance exercise regime.
Study: NCT02155049

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bimatoprost 0.03%
Description: The patients will receive a single daily drop of bimatoprost for six months.
Study: NCT03852108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comfort Care
Description: Face, Hand and body care for 15 to 45 minutes
Study: NCT02219698

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paracetamol
Study: NCT01947322

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic NK cells infusion
Description: HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
Study: NCT03747783

Intervention type: PROCEDURE
Intervention: Radical Operation
Description: The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.

Intervention type: PROCEDURE
Intervention: Radical Operation
Description: The surgery treatment selection was based on the American Joint Committee on Cancer stage both of the primary and of the recurrence, as well as on patterns of local spread that were not included in the T classification and on the general condition and preferences of each patient.
Study: NCT01597297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB041 (PR Fampridine)
Description: 10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
Study: NCT00263211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plavix

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Study: NCT02034162

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mebendazole
Description: Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
Study: NCT01445795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 200 mg INX-08189 Fasted
Description: 200 mg capsule INX-08189 fasted x7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo QD Fasted
Description: Placebo capsule QD fasted x7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg INX-08189 QD
Description: 100 mg INX-08189 capsule QD x 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo QD
Description: Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg INX-08189 with low-fat meal
Description: INX-08189 100 mg capsule, with low-fat meal QD for seven days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with low-fat meal
Description: Placebo capsule administered with a low-fat meal QD for seven days
Study: NCT01915901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bismuth subsalicylate (Pepto-Bismol®)
Description: 524 mg bismuth subsalicylate twice a day (BID)
Study: NCT01445795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg INX-08189 BID Fasted
Description: 100 mg INX-08189 BID fasted x7 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo BID Fasted
Description: Placebo BID fasted x7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Study: NCT02172911

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3112
Description: 1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: INO-3112
Description: 1.1 mL intramuscular (IM) injection of INO-3112 (VGX-3100 + INO-9012) was administered followed immediately by electroporation (EP) with CELLECTRA™-5P on Day 0, Week 4, Week 8, and Week 12.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™-5P
Description: CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CELLECTRA™-5P
Description: CELLECTRA™-5P was used for EP following IM delivery of INO-3112 on Day 0, Week 4, Week 8, and Week 12.
Study: NCT00127842

Intervention type: DRUG
Group type: OTHER
Intervention: Etanercept
Description: Administered according to the product monograph by subcutaneous (SC) injection
Study: NCT01095159

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-O
Description: Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TVT-S
Description: Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
Study: NCT01240538

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: wild-type reovirus
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT02077205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Manualised Cognitive Behavioral Therapy
Description: 16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
Study: NCT02209844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44847

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02619214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 30% of oxygen concentration.
Description: 30% oxygen concentration during one hour of general anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 60% of oxygen concentration.
Description: 60% oxygen concentration during one hour of general anesthesia.
Study: NCT03023722

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anetumab ravtansine
Description: Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle
Study: NCT00582725

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-CHOP+GM-CSF
Description: addition of GM-CSF
Study: NCT01053481

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D
Description: Vitamin D supplement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise program (rebounding on a trampoline)
Description: 40 days at 30 min/d
Study: NCT02425540

Intervention type: DEVICE
Intervention: Pelvic MRI
Study: NCT02828397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN2222
Study: NCT04154800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986209
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986209
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986209
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986209 Placebo
Description: Specified Dose on Specified Days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BMS-986209 Placebo
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Specified Dose on Specified Days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem
Description: Specified Dose on Specified Days
Study: NCT01377298

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 200mg/tablet, 800mg/day PO.
Study: NCT01377389

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: 10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide
Description: 7.5 mg intramuscular once a month for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: 3.6 mg subcutaneous once a month for 8 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: 80 mg subcutaneous once a month for 8 months
Study: NCT01928693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Besivance 0.6% Ophthalmic Suspension
Description: Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zymaxid 0.5% Ophthalmic Solution
Description: Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vigamox 0.5% Ophthalmic Solution
Description: Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
Study: NCT02882997

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: an interactive computer game
Description: Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard activities
Description: For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
Study: NCT01964846

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol, curcumin

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01193998

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as per model probability
Description: Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as per usual care
Description: Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
Study: NCT04429282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03930329

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBRP group
Description: same as arm description
Study: NCT02204020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-azacytidine (5-aza) maintenance therapy after transplant
Description: The planned initial dose of 5-aza is 32mg/m2 (Level 0) administered either subcutaneously or intravenously for days 1 through 5 of a 28-day cycle, which will be initiated between day+30 and day+100 after HCT. Patients who tolerate this dose based on hematologic parameters and with no SAEs for two consecutive cycles will be eligible for a dose escalation to 50mg/m2 (Level +1). Patients who tolerate this dose based on the same criteria as above for two consecutive cycles will be eligible for a dose escalation to 75mg/m² (Level +2). Patients will continue at dose Level +2 for the remainder of the study provided there are no toxicities that require dose reduction. Patients requiring a dose reduction are not eligible for re-escalation.
Study: NCT03815370

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Experimental: ABRO™ Binder Arm
Description: ABRO™ is an abdominal device designed to be positioned superficially on the abdominal skin of patients managed with the Open Abdomen strategy. The device is comprised of two rigid plates to stabilize the abdominal muscles thus preventing buckling of these. Another element of this novel device is the circumferential dynamic retainer (CDR). This one is passed behind the patient's back to provide more stability to the muscles in the abdomen keeping them in position to prevent lateral movement of them.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Usual Care
Description: The current approach for temporary coverage of abdomen is called vacuum assisted techniques (VAT). This technique requires the use of vacuum-assisted drainage to remove blood or watery fluid from a wound or operative site.
Study: NCT04082351

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Nanotechnology structured water ( Magnalife)
Description: Nanotechnology structured water ( Magnalife), is given as dietary supplement to the patients to drink it according to their weight .

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: ordinary water
Description: Ordinary bottled water
Study: NCT03602586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT02806492

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50-100ug phenylephrine before CPB
Description: In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP \<60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 50-100ug phenylephrine during CPB
Description: In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: decreasing CPB flow
Description: With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decreasing CPB flow AND 50-100ug phenylephrine
Description: In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing CPB flow
Description: In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
Study: NCT02751749

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Study: NCT02166970

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metallic stent deployment in hilar obstruction
Description: Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metallic stent deployment in hilar obstruction
Description: Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment
Study: NCT01667926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03708237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: ROPINIROLE has been approved by Health Canada for the treatment of idiopathic Parkinson's disease. Immediate release ropinirole is an orally administered non-ergoline dopamine agonist that is extensively metabolized by the liver. Ropinirole has not been approved by Health Canada for the treatment of moderate to severe RLS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: GABAPENTIN has been approved by Health Canada for the management of epilepsy. Immediate release gabapentin is an orally administered anticonvulsant primarily excreted through the kidneys. Gabapentin has not been approved by Health Canada for the treatment of moderate to severe RLS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Opaque gel capsules filled with methylcellulose 1500 filler